Electrophysiologic correlations with clinical outcomes in CIDP.
Data are lacking on correlations between changes in nerve conduction (NC) studies and treatment response in chronic inflammatory demyelinating polyneuropathy (CIDP). This report examined data from a randomized, double-blind trial of immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C [Gamunex]; n = 59) versus placebo (n = 58) every 3 weeks for up to 24 weeks in CIDP. Motor NC results and clinical measures were assessed at baseline and endpoint/week 24. Improvement from baseline in adjusted inflammatory neuropathy cause and treatment score correlated with improvement in proximally evoked compound muscle action potential (CMAP) amplitudes (r = -0.53; P < 0.001) of all nerves tested and with improvement in CMAP amplitude of the most severely affected motor nerve (r = -0.36; P < 0.001). Correlations were observed between improvement in averaged CMAP amplitudes and dominant-hand grip strength (r = 0.44; P < 0.001) and Medical Research Council sum score (r = 0.38; P < 0.001). Overall, the change in electrophysiologic measures of NC in CIDP correlated with clinical response to treatment.
Bril
Vera
V
Division of Neurology, University Health Network, 5EC-309, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4 Canada. vera.bril@utoronto.ca
Banach
Marta
M
Dalakas
Marinos C
MC
Deng
Chunqin
C
Donofrio
Peter
P
Hanna
Kim
K
Hartung
Hans-Peter
HP
Hughes
Richard A C
RA
Katzberg
Hans
H
Latov
Norman
N
Merkies
Ingemar S J
IS
Van Doorn
Pieter A
PA
D000200:Action Potentials; D000328:Adult; D000368:Aged; D002210:Caprylates / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D055724:Electrophysiological Phenomena; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008875:Middle Aged; D009046:Motor Neurons; D009431:Neural Conduction; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000503:physiopathology*; D016896:Treatment Outcome
D002210:Caprylates; D016756:Immunoglobulins, Intravenous